Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

被引：0
作者：
Alexa R Weingarden [1 ]
Samuel J S Rubin [2 ]
John Gubatan [1 ]
机构：
[1] Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University
[2] Stanford University School of Medicine, Stanford University
来源：
World Journal of Gastrointestinal Oncology | 2021年 / 08期
关键词：
D O I：
暂无
中图分类号：
R735 [消化系肿瘤]; R574.62 [结肠疾病];
学科分类号：
1002 ; 100201 ; 100214 ;
摘要：
Immune checkpoint inhibitors(ICI) have markedly changed the landscape of cancer therapy. By re-invigorating the immune system against tumors, ICI provide novel therapeutic options for a broad variety of malignancies, including many gastrointestinal(GI) cancers. However, these therapies can also induce autoimmune-like side effects in healthy tissue across the body. One of the most common of these side effects is ICI-mediated colitis and diarrhea(IMC). Here, we review the incidence and risk of IMC in ICI therapy, with a focus on what is known regarding IMC in patients with GI malignancies. We also discuss data available on the use of ICI and risk of IMC in patients with pre-existing inflammatory bowel disease, as these patients may have increased risk of IMC due to their underlying intestinal pathology.
引用
收藏
页码：772 / 798
页数：27
相关论文
共 63 条
  • [1] Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
    Jordan E Axelrad
    Simon Lichtiger
    Vijay Yajnik
    [J]. World Journal of Gastroenterology, 2016, 22 (20) : 4794 - 4801
  • [2] Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases[J] . Meserve Joseph,Facciorusso Antonio,Holmer Ariela K,Annese Vito,Sandborn William J,Singh Siddharth.Alimentary pharmacology & therapeutics . 2020
  • [3] Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer[J] . André Thierry,Shiu Kai Keen,Kim Tae Won,Jensen Benny Vittrup,Jensen Lars Henrik,Punt Cornelis,Smith Denis,Garcia Carbonero Rocio,Benavides Manuel,Gibbs Peter,de la Fouchardiere Christelle,Rivera Fernando,Elez Elena,Bendell Johanna,Le Dung T.,Yoshino Takayuki,Van Cutsem Eric,Yang Ping,Farooqui Mohammed Z.H.,Marinello Patricia,Diaz Luis A..New England Journal of Medicine . 2020 (23)
  • [4] Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy[J] . Roth Marc T,Das Satya.Expert review of anticancer therapy . 2020
  • [5] Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers[J] . Eso Yuji,Seno Hiroshi.Therapeutic advances in gastroenterology . 2020
  • [6] Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis
    Grover, Shilpa
    Dougan, Michael
    Tyan, Kevin
    Giobbie-Hurder, Anita
    Blum, Steven M.
    Ishizuka, Jeffrey
    Qazi, Taha
    Elias, Rawad
    Vora, Kruti B.
    Ruan, Alex B.
    Martin-Doyle, William
    Manos, Michael
    Eastman, Lauren
    Davis, Meredith
    Gargano, Maria
    Haq, Rizwan
    Buchbinder, Elizabeth I.
    Sullivan, Ryan J.
    Ott, Patrick A.
    Hodi, F. Stephen
    Rahma, Osama E.
    [J]. CANCER, 2020, 126 (16) : 3758 - 3767
  • [7] Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
    Luoma, Adrienne M.
    Suo, Shengbao
    Williams, Hannah L.
    Sharova, Tatyana
    Sullivan, Keri
    Manos, Michael
    Bowling, Peter
    Hodi, F. Stephen
    Rahma, Osama
    Sullivan, Ryan J.
    Boland, Genevieve M.
    Nowak, Jonathan A.
    Dougan, Stephanie K.
    Dougan, Michael
    Yuan, Guo-Cheng
    Wucherpfennig, Kai W.
    [J]. CELL, 2020, 182 (03) : 655 - +
  • [8] Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial[J] . Klein Oliver,Kee Damien,Nagrial Adnan,Markman Ben,Underhill Craig,Michael Michael,Jackett Louise,Lum Caroline,Behren Andreas,Palmer Jodie,Tebbutt Niall C,Carlino Matteo S,Cebon Jonathan.JAMA oncology . 2020
  • [9] Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis[J] . Hayashi Yukie,Hosoe Naoki,Takabayashi Kaoru,Limpias Kamiya Kenji J L,Tsugaru Kai,Shimozaki Keitaro,Hirata Kenro,Fukuhara Kayoko,Fukuhara Seiichiro,Mutaguchi Makoto,Sujino Tomohisa,Sukawa Yasutaka,Hamamoto Yasuo,Naganuma Makoto,Takaishi Hiromasa,Shimoda Masayuki,Ogata Haruhiko,Kanai Takanori.Digestive diseases and sciences . 2020
  • [10] Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review[J] . Michael Collins,Emilie Soularue,Lysiane Marthey,Franck Carbonnel.Clinical Gastroenterology and Hepatology . 2020 (6)
1234567